Lantheus Medical Imaging has acquired Meilleur Technologies, a deal that will give it exclusive global rights to Meilleur's NAV-4694 (F-18 flutafuranol) beta-amyloid PET imaging agent for Alzheimer's disease.
The purchase expands Lantheus' Alzheimer’s diagnostic portfolio and complements its F-18-labeled PET imaging agent candidate, MK-6240 (florquinitau), which targets tau tangles in Alzheimer's disease, according to the firm.
Under the terms of the agreement, Lantheus will make an upfront payment as well as potential additional development and commercial milestone payments. It will also make royalty payments for research revenue and commercial sales, it said.
![Pittsburgh Compound B (PiB) PET distribution volume ratio (DVR) images were projected onto fsaverage surfaces from FreeSurfer and surface smoothed, with PiB (amyloid) slope maps created using ordinary least squares regression (time as only factor) and mixed effects models for 154 participants run at each vertex (P < .01; model: longitudinal Geriatric Depression Scale score estimated by amyloid slope × time + [sex + education + age] × time). This map visualizes the results of the linear mixed-effects models (t score of the main variable, amyloid slope × time) such that regions with a greater t score (red) represent areas in which greater depressive symptoms are associated with greater amyloid accumulation (amyloid slope). Anatomical landmarks are provided: L refers to the left hemisphere, R refers to the right hemisphere, and additional labels indicate the anterior and posterior ends of the brain. Images available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of JAMA Open Network.](https://img.auntminnie.com/files/base/smg/all/image/2024/08/PET_depression.66cf997f7e441.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
